Literature DB >> 30568255

Cambridge Ophthalmological Symposium 2018: introduction and reflections on the day.

Marian Ludgate1.   

Abstract

I was privileged to be one of the co-chairs, along with Professor Tim Sullivan (Brisbane, Australia), for the Cambridge Ophthalmological Society (COS) annual international symposium, which, this year, was dedicated to thyroid eye disease (TED). Together with the organisers, Miss Rachna Murthy and Professor Keith Martin from COS, we compiled an impressive programme covering all aspects of the condition from events happening in a single orbital cell to improved surgical approaches.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30568255      PMCID: PMC6367334          DOI: 10.1038/s41433-018-0320-z

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  12 in total

1.  Development of an animal model of autoimmune thyroid eye disease.

Authors:  M C Many; S Costagliola; M Detrait; F Denef; G Vassart; M C Ludgate
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

2.  Regulation of Orbital Fibrosis and Adipogenesis by Pathogenic Th17 Cells in Graves Orbitopathy.

Authors:  Sijie Fang; Yazhuo Huang; Sisi Zhong; Yangyang Li; Yidan Zhang; Yinwei Li; Jing Sun; Xingtong Liu; Yang Wang; Shuo Zhang; Tianle Xu; Xiaodong Sun; Ping Gu; Dan Li; Huifang Zhou; Bin Li; Xianqun Fan
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

3.  Adipogenesis in thyroid eye disease.

Authors:  M Crisp; K J Starkey; C Lane; J Ham; M Ludgate
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

Review 4.  The microbiota and autoimmunity: Their role in thyroid autoimmune diseases.

Authors:  Hedda L Köhling; Sue F Plummer; Julian R Marchesi; Kelly S Davidge; Marian Ludgate
Journal:  Clin Immunol       Date:  2017-07-06       Impact factor: 3.969

5.  A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.

Authors:  Adina F Turcu; Seema Kumar; Susanne Neumann; Michael Coenen; Seethalakshmi Iyer; Pamela Chiriboga; Marvin C Gershengorn; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-03-12       Impact factor: 5.958

6.  Mesenchymal Stem Cell-Like Properties of Orbital Fibroblasts in Graves' Orbitopathy.

Authors:  Katarzyna Kozdon; Caroline Fitchett; Geoffrey E Rose; Daniel G Ezra; Maryse Bailly
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

7.  Autoantibodies to the IGF1 receptor in Graves' orbitopathy.

Authors:  Waldemar B Minich; Nora Dehina; Tim Welsink; Christian Schwiebert; Nils G Morgenthaler; Josef Köhrle; Anja Eckstein; Lutz Schomburg
Journal:  J Clin Endocrinol Metab       Date:  2012-12-21       Impact factor: 5.958

8.  Reversal of Pathological Features of Graves' Orbitopathy by Activation of Forkhead Transcription Factors, FOXOs.

Authors:  L Zhang; Q H Ji; F Ruge; C Lane; D Morris; A R Tee; C M Dayan; M Ludgate
Journal:  J Clin Endocrinol Metab       Date:  2015-10-26       Impact factor: 5.958

Review 9.  Immune regulatory function of B cells.

Authors:  Claudia Mauri; Anneleen Bosma
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

10.  Independent adipogenic and contractile properties of fibroblasts in Graves' orbitopathy: an in vitro model for the evaluation of treatments.

Authors:  He Li; Caroline Fitchett; Katarzyna Kozdon; Hari Jayaram; Geoffrey E Rose; Maryse Bailly; Daniel G Ezra
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.